All News

lupus_0.jpg

Exciting Data for SLE: Plenaries from #ACR22

Michael Putman, MD, MSCI

ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!

Read Article
lupus.jpg

Anifrolumab shows long-term promise in patients with lupus

EurekAlert!

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.

Read Article
acr_session2.jpeg

Industry Abstract Previews of ACR 2022

Jack Cush, MD

The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022.  These are their best studies for you to review and evaluate as part of your to-do list.

Read Article
Convention2.jpg

AS, Lupus and Subclinical RA: What I'm looking forward to at ACR22

Robert Chao, MD

As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.

Read Article
RheumNow Podcast square

Women with Rheumatic Disease (11.4.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

Read Article
Target,T2T,bullseye

SLE T2T - Lupus Low Disease Activity State Predicts Outcomes

Jack Cush, MD

Treat-to-target management of SLE has been shown to protect against organ damage and to improve quality of life. Now a prospective study shows that T2T with a goal of lupus low disease activity state and remission has been shown to improve mortality risk.

Read Article
DLE discoid lupus

ACR Promotes CME on Lupus Clinical Trials Racial Disparities

ACR

The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black p

Read Article
RheumNow Podcast square

Infections & Lupus (10.28.2022)

Jack Cush, MD

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Read Article
#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Plaquenil (HCQ) reduces #SLE mortality. Metanalysis (21 studies, 26,037 pts). Pooled findings - HCQ significantly reduced SLE mortality (HR 0.46); HCQ also reduced mortality in SLE pts w/ renal (HR=0.43), & cardiopulmonary dz (HR=0.37) https://t.co/fsHaN8wR17 https://t.co/MW8cvavzBC

Links:

Dr. John Cush RheumNow ( View Tweet)
Cluster analysis of 112 SLE pts looked at Erosive arthritis. Arthritis seen in 73%, arthralgia in 27%, erosive arthritis in 26%. Cluster that included erosive Dz also seen w/ CNS EL, serositis, Pos tests for ACPA, Carp, Sm, RNP, Dkk1 https://t.co/c7SLmFtweu https://t.co/qt9FdA1SBa

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 New Drug Approvals Download today! https://t.co/nz91Ckw0AZ https://t.co/QieTvcqjcy

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE T2T - Lupus Low Disease Activity State Predicts Outcomes A prospective study shows that T2T with a goal of LLDAS and remission has been shown to improve mortality risk. https://t.co/WRaqjdVi9G https://t.co/3guKt0Qby9

Links:

Dr. John Cush RheumNow ( View Tweet)
Infection: a Leading Cause of Death in Lupus Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE. https://t.co/uTQd3afwxR https://t.co/okBHWel62d

Links:

Dr. John Cush RheumNow ( View Tweet)
Increasing Risk of Lupus Nephritis A population based study shows that LN in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates 6x that of the general population. https://t.co/aBSUP9ExTh https://t.co/RfgSH0wmOu

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of serious infection (SIE) in SLE? A prior SIE conferred the highest risk of subsequent SIE. Study of 346 SLE pts shows SIE rate of 3.8/100 Pt-Yrs. Other risk factors: Damage accrual, comorbidity, Dz activity, CTX use https://t.co/hvAtpTUPml https://t.co/QkJp7ssOUU

Links:

Dr. John Cush RheumNow ( View Tweet)
Celebrating my 10,000 followers on TikTok. @Rheum101 is where I make videos teaching rheumatology to the general public in 3 min bites. Topics include #SLE #Steroids #RA #ANA #RheumLabs #DMARDS #biologics #JAKi #osteoporosis #PsA and more #RheumEducation #NotMedicalAdvice https://t.co/WEXspp5v28
TheDaoIndex KDAO2011 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×